| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 06/25/1992 | WO1992010097A1 Angiotensin ii receptor blocking compositions |
| 06/25/1992 | DE4041981A1 Use of selective and non-selective quisqualate receptor antagonists - combined with L-DOPA and/or dopamine agonists, for treatment of Parkinson's disease |
| 06/23/1992 | US5124471 Radiolabeling proteins |
| 06/23/1992 | US5124335 Substituted pyrollo-fused 6 membered heterocycles as angiotensin ii antagonists |
| 06/23/1992 | US5124314 Treatment of diabetes or hypoglycemia |
| 06/23/1992 | US5124147 Mixture of antagonist to platelet activating factor and antibody |
| 06/23/1992 | US5124146 Differential delivery of therapeutic agents across the blood brain barrier |
| 06/23/1992 | CA1303995C Effect of a combination of a beta-adrenergic agonist and certain histamine h -and/or h - receptor blockers on gastrointestinal injury produced by nonsteroidal anti-inflammatory compositions |
| 06/23/1992 | CA1303990C Solubilization of hydrophobic materials using lysophospholipids |
| 06/22/1992 | WO1992011012A1 Use of quisqualate-receptor antagonists for treating parkinson's disease |
| 06/22/1992 | CA2076524A1 New use of quisqualate receptor antagonists |
| 06/22/1992 | CA2055661A1 Treatment of upset stomach associated with heartburn, sour stomach or acid indigestion with an effervescent h2 blocker formulation |
| 06/20/1992 | WO1992011037A2 Targeting of therapeutic agents using polysaccharides |
| 06/19/1992 | WO1992011034A1 Agents for potentiating the effects of antitumor agents and combating multiple drug resistance |
| 06/19/1992 | CA2098198A1 Agents for potentiating the effects of antitumour agents and combating multiple drug resistance |
| 06/18/1992 | WO1992011035A1 Improved treatment method for cancer |
| 06/17/1992 | EP0490380A2 Use of N,N'-bis 3-(ethylamino)propyl -1,7-heptanediamine and a cytotoxic agent |
| 06/17/1992 | EP0490305A2 Microspheres for ophthalmic use |
| 06/17/1992 | EP0490250A2 Use of interferon and an antimalarial agent for the treatment of malarial infections |
| 06/17/1992 | DE4039631A1 Neuro-protective combination for treating cerebral ischaemia - contains a 5-HT1A receptor agonist and 5-HT2 receptor antagonist |
| 06/16/1992 | CA1303531C Choriocarcinoma monoclonal antibodies and antibody panels |
| 06/13/1992 | CA2055522A1 Microspheres for ophthalmic use |
| 06/10/1992 | EP0489404A2 Method of treating shock using a potassium channel activator |
| 06/09/1992 | US5120834 Fibrin-specific monoclonal antibody |
| 06/09/1992 | US5120713 Treatment of obesity with an alpha-2-adrenergic agonist and a growth hormone releasing peptide |
| 06/09/1992 | CA1303294C .alpha.-HYDROXY THIOETHERS |
| 06/09/1992 | CA1303292C Anhydrous enhanced coupling |
| 06/08/1992 | CA2057157A1 Use of interferon and a substance with an antimalarial activity for the treatment of malaria infections |
| 06/07/1992 | WO1992010205A1 Synergistic compositions of soluble complement receptors and compounds that inhibit complement and/or suppress immune activity |
| 06/07/1992 | CA2097825A1 Synergistic compositions of soluble complement receptors and compounds that inhibit complement and/or suppress immune activity |
| 06/06/1992 | WO1992010228A1 Devices for treating pulmonary vasoconstriction and asthma |
| 06/06/1992 | CA2055376A1 Method of treating shock using a potassium channel activator |
| 06/03/1992 | EP0488959A2 New uses of competitive NMDA receptor antagonists |
| 06/03/1992 | EP0488401A1 A controlled-release pharmaceutical preparation for intra-ocular implant |
| 06/03/1992 | EP0488137A2 Preparation for transdermal drug administration |
| 06/03/1992 | EP0488059A2 Use of a combination of an ace inhibitor with a calcium antagonist in the treatment of proteinuria |
| 06/03/1992 | CN1061594A Hydroxyalkylquineline ether acids as leakotaiene antagonists |
| 06/02/1992 | US5118670 Process and composition for increasing brain dopamine release |
| 06/02/1992 | US5118667 Bone growth factors and inhibitors of bone resorption for promoting bone formation |
| 06/02/1992 | US5118500 Side effect reduction when administering a xanthine derivative |
| 06/02/1992 | CA1302324C Ex vivo effector cell activation for target cell killing |
| 06/02/1992 | CA1302271C Method of promoting wound-healing |
| 06/02/1992 | CA1302268C Pharmaceutical compositions containing diltiazem and an enzyme inhibitor |
| 05/31/1992 | CA2056513A1 A controlled-release pharmaceutical preparation for intra-ocular implant |
| 05/28/1992 | WO1992009286A1 Composition containing antihistamine h2 receptor antagonists and bioadhesive material |
| 05/28/1992 | CA2096962A1 Composition containing antihistamine h2 receptor antagonists and bioadhesive material |
| 05/27/1992 | EP0487502A2 Pharmaceutically active aryl-substituted amine derivatives |
| 05/27/1992 | EP0486809A2 Use of suramin against TNF-related diseases |
| 05/27/1992 | EP0486526A1 Tumour necrosis factor binding ligands. |
| 05/27/1992 | CN1061408A Saturated hydroxyalkylquinoline acids as leukotriene antagonists |
| 05/26/1992 | US5116603 Oral antifungal preventative, and method of use |
| 05/26/1992 | CA1301654C Composition for the topical treatment of glaucoma or ocular hypertension |
| 05/20/1992 | EP0485486A1 Process for disinfecting musculoskeletal tissue and tissues prepared thereby. |
| 05/19/1992 | US5114929 Oral administration of antibiotics from an unpressurized container |
| 05/14/1992 | WO1992004014A3 Regulation of neoplastic cell proliferation via a novel 5ht1a receptor |
| 05/14/1992 | WO1991016903A3 Use of purine derivatives for anesthesia, analgesia and in vivo organ preservation |
| 05/13/1992 | EP0485111A2 The use of lipoxygenase and cyclooxygenase inhibitors as synergistic agents |
| 05/13/1992 | EP0484437A1 Renal-selective prodrugs for the treatment of hypertension |
| 05/13/1992 | EP0195015B1 Pharmaceutical composition for combination therapy of hormone dependent cancers |
| 05/12/1992 | US5112954 Antibodies specific for cancer cells |
| 05/12/1992 | US5112844 Micelles |
| 05/12/1992 | US5112608 Use of protease nexin-I to mediate wound healing |
| 05/12/1992 | CA1300510C Stabilized composition containing angiotensin converting enzyme |
| 05/08/1992 | WO1992008456A2 Method of inhibiting transformation, growth and metastasis of cells in which purine metabolic enzyme activity is elevated |
| 05/08/1992 | CA2095732A1 Method of inhibiting transformation, growth and metastasis of cells in which purine metabolic enzyme activity is elevated |
| 05/07/1992 | CA2054312A1 Synergistic agents |
| 05/06/1992 | WO1992007580A1 Therapeutic uses of melanin |
| 05/06/1992 | EP0453515A4 Composition and method for treatment of senile dementia |
| 05/06/1992 | CN1060851A Prolonged release preparation and polymers thereof |
| 05/06/1992 | CN1060788A Synergism of tnf and il-4 |
| 05/05/1992 | CA1300058C Process for preparing activated killer cells |
| 04/30/1992 | WO1992007083A1 Antibodies against the urokinase receptor and their use |
| 04/30/1992 | WO1992006713A1 Pharmaceutical composition containing an ace inhibitor and an inhibitor of thromboxane a2 activity for treating nephropathies |
| 04/29/1992 | EP0482498A2 Method for preventing diabetic complications employing a cholesterol lowering drug alone or in combination with an ace inhibitor |
| 04/29/1992 | EP0482493A2 Pharmaceutical compositions active in the therapy of neurological affections in aids patients, containing as an active principle at last one compound selected from the group consisting of S-adenosyl-L-methionine salt, 5-methyl-tetrahydrofolic acid, 5-formyltetrahydrofolic acid |
| 04/29/1992 | CN1060599A 化妆品组合物 Cosmetic composition |
| 04/28/1992 | US5108758 Glassy amylose and a therapeutical or diagnostically active compound; for treating ulcerative colitis, crohm's desease and cancer of colon |
| 04/28/1992 | CA1299583C Effervescent couples, histamine h -antagonist effervescent compositions containing them and their preparation |
| 04/22/1992 | EP0481732A1 Prolonged release preparation and polymers thereof |
| 04/22/1992 | EP0481701A1 Treatment composition |
| 04/22/1992 | EP0481207A1 Method for preventing or inhibiting loss of cognitive function employing a combination of an ace inhibitor and a drug that acts at serotonin receptors |
| 04/22/1992 | EP0480950A1 Combination therapy for prophylaxis and/or treatment of benign prostatic hyperplasia |
| 04/21/1992 | US5106955 Process for preparation of antibody conjugates |
| 04/21/1992 | US5106954 Erythropoietin (epo) peptides |
| 04/21/1992 | US5106746 Process for the in vitro immunization of human splenocytes against tumor associated antigens |
| 04/21/1992 | US5106610 Method for determining the diuretic potency of candidate drugs as inhibitors of the antidiuretic hormone-elicited water channel |
| 04/20/1992 | CA2052014A1 Method for preventing diabetic complications employing a cholesterol lowering drug alone or in combination with an ace inhibitor |
| 04/16/1992 | WO1992005805A1 Synergism of tnf and il-4 |
| 04/16/1992 | WO1992005803A1 Self-assembling ion pair drugs |
| 04/16/1992 | WO1992005784A1 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridine derivatives and analogues as angiotensin ii receptor antagonists |
| 04/16/1992 | WO1992004015A3 Regulation of t-cell proliferation via a novel 5ht1a receptor |
| 04/16/1992 | WO1992002240A3 Novel methods and compositions for treatment of angiogenic diseases |
| 04/15/1992 | EP0480716A1 Saturated hydroxyalkylquinoline acids as leukotriene antagonists |
| 04/15/1992 | EP0480708A2 Hydroxyalkylquinoline ether acids as leukotriene antagonists |
| 04/15/1992 | EP0480659A2 Use of Angiotensin-II antagonists for the manufacture of a medicament for the treatment of hyperuricemia |
| 04/15/1992 | EP0480315A2 Use of a retinoid |
| 04/15/1992 | EP0480257A2 Use of a potassium channel activator for pharmaceutical compositions useful in cardiopulmonary bypass and organ transplant |
| 04/15/1992 | EP0480054A1 Percutaneously absorbable composition of morphine hydrochloride |
| 04/15/1992 | EP0479892A1 Fused-ring aryl substituted imidazoles |
| 04/15/1992 | EP0357725B1 Pharmaceutical composition for treatment of lung obstructions |